Journal of Pharmaceutical Investigation

The Korean Society of Pharmaceutical Sciences and Technology (한국약제학회)
권호 표지
DOI QR코드

DOI QR Code

Screening of Anticancer Potential of Celecoxib and its Derivatives

셀레콕시브 및 그 합성유도체들의 항암활성 스크리닝

  • Published : 2003.06.20
Download PDF
⟨ Previous Next ⟩

Abstract

Selective COX (cyclooxygenase)-2 inhibitors including celecoxib have been shown to induce apoptosis and cell cycle changes in various tumor cells. New inhibitors are recently being developed as chemomodulating agents. We evaluated celecoxib and screened 150 synthetic compounds for anti-proliferative activities in vitro. Effects of celecoxib on COX activity, cell growth, cell cycle distribution, and apoptosis induction were determined in A549 COX-2 overexpressing human non-small cell lung cancer (NSCLC) cells. The COX inhibition of celecoxib increased with concentration up to 82% at $1\;{\mu}M$ after 24 hr exposure. Forty ${\mu}M$ and $50\;{\mu}M$ of ce1ecoxib induced $G_1$ arrest, and TUNEL-positive apoptotic cells, respectively. Among 150 compounds, several compounds were selected for having greater COX-2 inhibitory activity and higher selectivity than celecoxib with growth inhibitory activity. Celecoxib showed concentration-dependent COX inhibitory activity, and ability to induce cell cycle arrest and apoptosis in human NSCLC cells in vitro. Among synthetic analogues screened, several compounds showed promising in vitro activity as COX-2 inhibitory anticancer agents, which warrant further evaluation in vitro and in vivo.

Keywords

References

  1. R.E. Harris, Cycloxygenase-2, prostaglandins, and colorectal carcinogenesis. In COX-2 Blockade In Cancer Prevention and Therapy, Humana Press., pp. 160-164 (2003).
  2. A.T. Koki and J.L. Masferrer, Celecoxib, a specific COX-2 inhibitor with anticancer properties, Cancer Control., 9, 28-35 (2002). https://doi.org/10.1177/107327480200902S04
  3. S. $Gr\ddot{o}sch,$ I. Tegeder, E. Niederberger, L. Brautigam and G. Geisslinger, COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J., 15, 2742-2744(2001). https://doi.org/10.1096/fj.01-0299fje
  4. T. Hida, K. Kozaki, H. Muramatsu, A. Masuda, S. Shimizu, T. Mitsudomi, T. Sugiura, M. Ogawa and T. Takahashi, Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin. Cancer Res., 6, 2006-2011 (2000)
  5. M.M. Goldenberg, Celecoxib, a selective cyclooxygenase-2 inhibitor for the treatment of rheumatoid arthritis and osteoarthritis. Clin. Ther., 21, 1497-1513; discussion 1427-1428 (1999) https://doi.org/10.1016/S0149-2918(00)80005-3
  6. N.H. Holford and L.B. Sheiner, Kinetics of pharmacologic response. Pharmacal. Ther., 16, 143-166 (1982) https://doi.org/10.1016/0163-7258(82)90051-1
  7. W.C. Hung, H.C. Chang, M.R. Pan, T.H. Lee and L.Y. Chuang, Induction of p27(KIPI) as a mechanism underlying NS398-induced growth inhibition in human lung cancer cells. Mol. Pharmacol., 58, 1398-1403 (2000) https://doi.org/10.1124/mol.58.6.1398
  8. Y. Araki, S. Okamura, S.P. Hussain, M. Nagashima, P. He, M. Shiseki, K. Miura and C.C. Harris, Regulation of cyclooxygenase-2 expression by the wnt and ras pathways. Cancer Res., 63, 728-734 (2003)
  9. J.A. Han, J.I. Kim, P.P. Ongusaha, D.H Hwang, L.R. Ballou, A Mahale, S.A Aaronson and S.W Lee, p53mediated induction of Cox-2 counteracts p53-or genotoxic stress-induced apoptosis. EMBO J., 21, 5635-5644 (2002) https://doi.org/10.1093/emboj/cdf591
  10. J. Cheng, H. Imanishi, Y. Amuro and T. Hada, NS-398, a selective cyclooxygenase 2 inhibitor, inhibited cell growth and induced cell cycle arrest in human hepatocellular carcinoma cell lines. Int. J. Cancer., 99, 755-761 (2002) https://doi.org/10.1002/ijc.10409
  11. D.H. Hwang, V. Fung and A.J. Dannenberg, National Cancer Institute workshop on chemopreventive properties of nonsteroidal anti-inflammatory drugs: role of Cox-dependent and independent mechanisms. Neoplasia., 4, 91-97 (2002) https://doi.org/10.1038/sj.neo.7900226
  12. X. Song, H.P. Lin, A.J. Johnson, P.H. Tseng, Y.T. Yang, S.K. Kulp and C.S. Chen, Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells. J. Natl. Cancer Inst., 94, 585-591 (2002) https://doi.org/10.1093/jnci/94.8.585
  13. S.J. Baek, K.S. Kim, J.B. Nixon, L.C. Wilson and T.E. Eling, Cyclooxygenase inhibitors regulate the expression of a TGFbeta superfamily member that has proapoptotic and antitumorigenic activities. Mol. Pharmacol., 59, 901-908 (2001) https://doi.org/10.1124/mol.59.4.901
  14. S.J. Baek, L.C. Wilson, C.H. Lee and T.E. Eling, Dual function of nonsteroidal anti-inflammatory drugs (NSAlDs): inhibition of cyclooxygenase and induction of NSAID-activated gene. J. Pharmacal. Exp. Ther., 301, 1126-1131 (2002) https://doi.org/10.1124/jpet.301.3.1126
  15. AL. Hsu, T.T. Ching, D.S. Wang, X. Song, Y.M. Rangnekar and C.S. Chen, The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J. Biol. Chem.,275, 11397-11403 (2000) https://doi.org/10.1074/jbc.275.15.11397
  16. S. Arico, S. Pattingre, C. Bauvy, P. Gane, A. Barbat, P. Codogno and E. Ogier-Denis, Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line. J. Bioi.Chern., 277, 27613-27621 (2002) https://doi.org/10.1074/jbc.M201119200
  17. L.C. Hsi, S.l Baek and T.E. Eling, Lack of cyclooxygenase-2 activity in HT-29 human colorectal carcinoma cells. Exp. Cell Res., 256, 563-570 (2000) https://doi.org/10.1006/excr.2000.4863
  18. L. Milas, K. Kishi, N.Hunter, K. Mason, J.L. Masferrer and P.J. Tofilon, Enhancement of tumor response to gammaradiation by an inhibitor of cyclooxygenase-2 enzyme. J. Natl. Cancer Inst., 91, 1501-1504 (1999) https://doi.org/10.1093/jnci/91.17.1501
  19. A.F. Soriano, B. Helfrich, D.C. Chan, L.E. Heasley, PA. Jr. Bunn and T.C. Chou, Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines. Cancer Res., 59, 61786184 (1999)
  20. T.Hida, K. Kozaki, H. Ito, O. Miyaishi, Y. Tatematsu, T. Suzuki, K. Matsuo, T. Sugiura, M. Ogawa, T. Takahashi and T. Takahashi, Significant growth inhibition of human lung cancer cells both in vitro and in vivo by the combined use of a selective cyclooxygenase 2 inhibitor, JTE-522, and conventional anticancer agents. Clin. Cancer Res., 8, 2443-2447 (2002)
  21. K. Wakitani, T Nanayama, M. Masaki and M. Matsushita, Profile of ITE-522 as a human cyclooxygenase-2 inhibitor. Jpn. J. Pharmacol., 78, 365-371 (1998)
  22. Y. Mizutani, K. Kamoi, O. Ukimura, A. Kawauchi and T. Miki, Synergistic cytotoxicity and apoptosis of JTE-522, a selective cyclooxygenase-2 inhibitor, and 5-fluorouracil against bladder cancer. J. Ural., 168, 2650-2654 (2002) https://doi.org/10.1016/S0022-5347(05)64237-1